Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback